Has Tecentriq earned a role in treatment of triple-negative breast cancer? Here is what experts say

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Obviously, the field of immune-oncology has been one of the great success stories in our field over the last five years, based on our molecular understanding of the mechanisms of immune tolerance (or checkpoints) and how to disrupt that. Not only has ASCO declared Checkpoint Inhibition (as well as cellular-based immunotherapy) the “Advance of the Year,” the Nobel Committee awarded this year’s Prize to Drs. Allison and Honjo for their fabulous observations that led to these great breakthroughs.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Stuart B. Padnos Professor of Breast Cancer Research, University of Michigan Rogel Cancer Center
Chief scientific and medical officer, American Cancer Society
Former member of the FDA Oncologic Drugs Advisory Committee
Ballvé Lantero Professor of Oncology, IU School of Medicine, Associate director of clinical research, Indiana University Melvin and Bren Simon Cancer Center
Table of Contents

YOU MAY BE INTERESTED IN

President Joe Biden has announced his intent to appoint Monica Bertagnolli as the 16th director of the National Cancer Institute—and the first woman and first chair of a clinical trials cooperative group to be named to the role.The White House announcement Aug. 10 comes nearly three weeks after news of Bertagnolli’s appointment leaked out on Twitter and in the press (The Cancer Letter, July 21, 2022).
Can you imagine, as a radiation oncologist, you have to shelter your patients in a Co-60 vault to protect them from missiles, provide them with water by melting snow, feed them, keep them warm by using a backup power generator, and evacuate them just two hours before the missile destroys the radiation oncology department? 
Research shows that cancer patients who receive navigation have improved survival, access to advanced care like clinical trials, and services like genetic testing and palliative care. Navigation often results in increased screening and patients receiving treatment sooner, resulting in improved quality of life and more cancer-free days.
Stuart B. Padnos Professor of Breast Cancer Research, University of Michigan Rogel Cancer Center
Chief scientific and medical officer, American Cancer Society
Former member of the FDA Oncologic Drugs Advisory Committee
Ballvé Lantero Professor of Oncology, IU School of Medicine, Associate director of clinical research, Indiana University Melvin and Bren Simon Cancer Center

Login